Enanta reported a narrower-than-expected net loss of $0.45 per share for fiscal Q2 2026, beating the consensus estimate of -$0.51 by 11.8%, while revenue of $17.2M exceeded the $16.8M consensus, driven by higher AbbVie royalty revenue; the company also initiated dosing in a Phase 1 trial of EDP-978 and advanced its RSV pipeline toward a registrational trial, reinforcing its clinical-stage catalyst trajectory.
ENTA drugs
ENTA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $13.52entry
- T+1 · 3mo ago −0.15%α −0.40% · $13.50
- T+5 · 3mo ago −1.63%α −1.22% · $13.30
- T+20 · 2mo ago −2.07%α −1.01% · $13.24
- T+60 · 13d ago −21.23%α −20.74% · $10.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Enanta reported a narrower-than-expected net loss of $0.45 per share for fiscal Q2 2026, beating the consensus estimate of -$0.51 by 11.8%, while revenue of $17.2M exceeded the $16.8M consensus, driven by higher AbbVie royalty revenue; the company also initiated dosing in a Phase 1 trial of EDP-978 and advanced its RSV pipeline toward a registrational trial, reinforcing its clinical-stage catalyst trajectory.
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342336 |
| Document: enta-20260810.htm | 0001193125-26-342336 |
| Document: 0001193125-26-342336-index-headers.html | 0001193125-26-342336 |
| Document: 0001193125-26-342336-index.html | 0001193125-26-342336 |
| Document: 0001193125-26-342336.txt | 0001193125-26-342336 |
| 8-K Data (Synthetic) | 0001193125-26-342336 |
Track record
7 reports on ENTA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $11.20 Now $10.67 −4.73% settles Nov 24
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $10.99 Now $10.67 +2.91% settles Nov 23
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $11.22 Now $10.67 −4.90% settles Nov 17
- Oct 29, 202618d ago 8-K Bearish 7/10 Entry $10.71 to $11.00 Now $10.67 +0.37% ▼ −2.71% −5.41% vs SPY
- Oct 28, 202619d ago 8-K Neutral 3/10 Entry $11.55 to $10.65 Now $10.67 −7.62% ▼ −7.79% −7.08% vs SPY
- Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $11.55 to $10.65 Now $10.67 −7.62% ▼ −7.79% −7.08% vs SPY
- Aug 10, 202614w ago 8-K Bullish 7/10 Viewing Entry $13.52 to $13.30 Now $10.67 −21.08% ▼ −1.63% −1.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers